No, the IV thrombolysis window has NOT been extended to 6 hours as standard practice
The current evidence-based treatment window for intravenous thrombolysis in acute ischemic stroke is 4.5 hours from symptom onset, not 6 hours. This represents the established guideline recommendation based on the ECASS-3 trial and subsequent AHA/ASA guidance 1.
Current Standard Treatment Window
The 2009 AHA/ASA Science Advisory established that rtPA can be administered between 3 and 4.5 hours after stroke onset based on the ECASS-3 trial, which demonstrated:
- Improved functional outcomes (mRS 0-2) compared to placebo
- Increased symptomatic ICH risk (2.4% vs 0.2% by ECASS-3 definition; 7.9% vs 3.5% by NINDS definition)
- Specific exclusion criteria: age >80 years, NIHSS >25, oral anticoagulant use, or combination of prior stroke plus diabetes 1
The 6-Hour Question: Research vs. Reality
While research suggests potential benefit up to 6 hours with imaging selection, this has NOT translated into standard guideline approval:
Evidence Supporting Extended Window:
- Recent meta-analyses (2026) show IVT beyond 4.5 hours in imaging-selected patients improves functional outcomes 2, 3
- Number needed to treat: 12-16 for favorable outcome
- Number needed to harm: 62 for symptomatic ICH 2
Critical Limitations:
- All extended window studies require advanced imaging selection (DWI/PWI mismatch, perfusion imaging)
- Treatment effect declines rapidly: NNT of 7 at 0-3 hours vs. >30 at 3-6 hours 4
- The 2002 meta-analysis showed benefit up to 6 hours had wide confidence intervals and lacked statistical robustness 5
Clinical Algorithm for Treatment Timing
0-3 hours: Standard rtPA (0.9 mg/kg, max 90 mg) - strongest evidence, fewest restrictions
3-4.5 hours: rtPA with additional exclusions:
- Exclude if age >80
- Exclude if NIHSS >25
- Exclude if on oral anticoagulants
- Exclude if prior stroke + diabetes
4.5-24 hours: NOT standard practice
- Consider only in research protocols or with institutional approval
- Requires perfusion imaging demonstrating salvageable penumbra
- Patient/family must understand off-label use
- Tenecteplase showing promise but not yet standard 6, 7
Common Pitfalls to Avoid
Do not confuse research findings with approved practice - Multiple studies discuss 6-hour windows, but these are investigational or require specific imaging protocols not universally available
Do not treat beyond 4.5 hours without imaging-based selection - The "tissue window" concept requires demonstration of viable penumbra, not just elapsed time
Do not ignore the additional exclusion criteria for the 3-4.5 hour window - These restrictions exist because ECASS-3 specifically excluded these higher-risk populations
The time is "last known well," not "arrival time" - Wake-up strokes or unclear onset times require imaging-based assessment, not assumption of eligibility
The evidence base continues evolving with newer agents like tenecteplase and better imaging selection, but the current standard remains 4.5 hours maximum for routine clinical practice 1.